Case Study Of PAREXEL International
Slide 1
Boston is the first place of our Future Leading Program. This city is located in the northeastern United States.
Our destination was PAREXEL International and we received some lectures at PAREXEL International.
Slides 2
Nothing
Slides 3
Before talking about our experiences, please allow me to introduce about this company, briefly.
These are some key words and basic information.
PAREXEL’s business is to support drug development. It is called contract research organization.
PAREXEL was founded in 1982 and has 18,660 employees, operating in 80 locations in 51 countries.
I would like to focus on two features.
First, PAREXEL is a contract research organization that partners with pharmaceutical, biotechnology and medical device industries. …show more content…
Alberto taught us the reason. South Africa is a good place because it has a good university and very skilled people. Additionally, they can conduct clinical trials at lower costs than other countries. Therefore, it is an attractive place to do business.
These are some of the differences from Japan. In order to achieve the global development of medicine, it is necessary for us to understand the culture and regulatory requirements of each country.
Slides 8
We had precious time at PAREXEL International and were tired a little due to the jet-rug.
Slides 9
We had a flight from Boston to Washington D.C. It takes about one and a half hour.
The city is the second place of our Future Leading Program and is located in the Mid-Atlantic region of the east coast of the United States.
We visited H3Biomedicine inc., Food and Drug Administration, U. S. Pharmacopeial Convention, DIA Headquarter, and receive some lectures as well as discussion there.
In addition, we participated in DIA 51st annual meeting
Slides 10
We could communicate and discuss about medicines from each perspective, industry and regulatory authority, organization.
Slides 11
We moved from Washington D.C. to Seattle. It takes about six …show more content…
Their main roles are to provide human resources and support the development process.
It is attractive for medical product manufacturers to reinforce their own labor forces without the need for more training or increasing the number of employees. This means that they don’t have to invest in human resources more than necessary.
Moreover, CROs enable medical companies to accelerate the development process 30% faster. This value brings to patients the increased likelihood of access new medical products in a more timely fashion.
Therefore, in simple terms, CROs are crucial collaborators throughout the development process.
Slide 2
Please take a look at this figure.
This shows the importance of CROs for pharmaceutical and biotechnology companies. The vertical axis shows the minimum number of employees to develop products and the horizontal axis shows time.
The minimum number can vary from period to period, because these companies are unable to maintain a constant number of products. This is usually influenced by clinical trial stages and outcomes. If companies employed a surplus labor force, they may still spend wastefully. However, even if they have a smaller number of employees below the minimum number of employees, they can still outsource drug development to CROs so that it will
Boston is the first place of our Future Leading Program. This city is located in the northeastern United States.
Our destination was PAREXEL International and we received some lectures at PAREXEL International.
Slides 2
Nothing
Slides 3
Before talking about our experiences, please allow me to introduce about this company, briefly.
These are some key words and basic information.
PAREXEL’s business is to support drug development. It is called contract research organization.
PAREXEL was founded in 1982 and has 18,660 employees, operating in 80 locations in 51 countries.
I would like to focus on two features.
First, PAREXEL is a contract research organization that partners with pharmaceutical, biotechnology and medical device industries. …show more content…
Alberto taught us the reason. South Africa is a good place because it has a good university and very skilled people. Additionally, they can conduct clinical trials at lower costs than other countries. Therefore, it is an attractive place to do business.
These are some of the differences from Japan. In order to achieve the global development of medicine, it is necessary for us to understand the culture and regulatory requirements of each country.
Slides 8
We had precious time at PAREXEL International and were tired a little due to the jet-rug.
Slides 9
We had a flight from Boston to Washington D.C. It takes about one and a half hour.
The city is the second place of our Future Leading Program and is located in the Mid-Atlantic region of the east coast of the United States.
We visited H3Biomedicine inc., Food and Drug Administration, U. S. Pharmacopeial Convention, DIA Headquarter, and receive some lectures as well as discussion there.
In addition, we participated in DIA 51st annual meeting
Slides 10
We could communicate and discuss about medicines from each perspective, industry and regulatory authority, organization.
Slides 11
We moved from Washington D.C. to Seattle. It takes about six …show more content…
Their main roles are to provide human resources and support the development process.
It is attractive for medical product manufacturers to reinforce their own labor forces without the need for more training or increasing the number of employees. This means that they don’t have to invest in human resources more than necessary.
Moreover, CROs enable medical companies to accelerate the development process 30% faster. This value brings to patients the increased likelihood of access new medical products in a more timely fashion.
Therefore, in simple terms, CROs are crucial collaborators throughout the development process.
Slide 2
Please take a look at this figure.
This shows the importance of CROs for pharmaceutical and biotechnology companies. The vertical axis shows the minimum number of employees to develop products and the horizontal axis shows time.
The minimum number can vary from period to period, because these companies are unable to maintain a constant number of products. This is usually influenced by clinical trial stages and outcomes. If companies employed a surplus labor force, they may still spend wastefully. However, even if they have a smaller number of employees below the minimum number of employees, they can still outsource drug development to CROs so that it will